MKI67 and cervical carcinoma: Due to increasing cervical cancer rates in women aged 25–29 years, we investigated in our study whether primary HPV screening with triage HPV-positive cases with the p16/Ki67 biomarker can be an alternative screening strategy to cytology-based screening in young women under age 30 years.